Headlines about Avrobio (NASDAQ:AVRO) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Avrobio earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.9455551834006 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

A number of analysts have recently weighed in on the company. Wedbush assumed coverage on Avrobio in a research note on Monday, July 16th. They issued an “outperform” rating and a $38.00 target price for the company. Wells Fargo & Co assumed coverage on Avrobio in a research note on Monday, July 16th. They issued an “outperform” rating and a $40.00 target price for the company. Morgan Stanley assumed coverage on Avrobio in a research note on Monday, July 16th. They issued an “overweight” rating and a $37.00 target price for the company. Finally, Cowen assumed coverage on Avrobio in a research note on Monday, July 16th. They issued an “outperform” rating for the company.

Shares of NASDAQ:AVRO traded up $0.59 during midday trading on Friday, reaching $33.24. The company’s stock had a trading volume of 186,624 shares, compared to its average volume of 47,737. Avrobio has a fifty-two week low of $26.51 and a fifty-two week high of $44.01.

Avrobio (NASDAQ:AVRO) last announced its earnings results on Thursday, August 9th. The company reported ($2.98) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($2.51). equities analysts anticipate that Avrobio will post -4.81 earnings per share for the current year.

Avrobio Company Profile

AVROBIO, Inc, a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease.

Featured Story: Market Capitalization in the Stock Market

Insider Buying and Selling by Quarter for Avrobio (NASDAQ:AVRO)

Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.